Don't forget the exogenous microbial transglutaminases: It is immunogenic and potentially pathogenic

AIMS Biophysics

Volumn 3, Issue 4, 2016, Pages 546-552

  Lerner, Aaron ^a,b   Matthias, Torsten ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b AESKUKIPP Institute   (Germany)

Author keywords

Antibodies; Environment; Immunogenicity; Mechanism; Microbial transglutaminase; Pathogenicity; Transglutaminases

Indexed keywords

EID: 85018198338     PISSN: None     EISSN: 23779098     Source Type: Journal    
DOI: 10.3934/biophy.2016.4.546     Document Type: Article

References (34)

1. Lerner A, Neidhöfer S, Matthias T (2015) Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond: Part A: TG2 double-edged sword: gut and extraintestinal involvement. Immunome Res 11: 101-105.
2. Lerner A, Neidhöfer S, Matthias T (2015) Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond. Part B: Anti-Transglutaminase 2 autoantibodies: friends or enemies. Immunome Res 11: 3-7.
3. Lerner A, Jeremias P, Neidhöfer S, et al. (2016) Antibodies against neo-epitope tTg complexed to gliadin are different and more reliable then anti-tTg for the diagnosis of pediatric celiac disease. J Immunol Methods 429: 15-20.
4. Gatta NG, Cammarota G, Gentile V (2016) Possible roles of transglutaminases in molecular mechanisms responsible for human neurodegenerative diseases. AIMS Biophysics 3: 529-545.
5. Lerner A, Matthias T (2015) Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev 14: 479-489.
6. Lerner A, Matthias T (2015) Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutr Rev 73: 544-552.
7. Kieliszek M, Misiewicz A (2014) Microbial transglutaminase and its application in the food industry. A review. Folia Microbiol 59: 241-250.
8. Adapted from Freedonia Group Inc. World enzymes forecast for 2015 and 2020;Dec 2011.
9. Malandain H (2005) Transglutaminases: a meeting point for wheat allergy, celiac disease, and food safety. Eur Ann Allergy Clin Immunol 37: 397-403.
10. Elli L, Roncoroni L, Hils M, et al. (2012) Immunological effects of transglutaminase-treated gluten in coeliac disease. Hum Immunol 73: 992-997.
11. Falini ML, Elli L, Caramanico R, et al. (2008) Immunoreactivity of antibodies against transglutaminase-deamidated gliadins in adult celiac disease. Dig Dis Sci 53: 2697-2701.
12. Heredia-Sandoval NG, Islas-Rubio AR, Cabrera-Chávez F, et al. (2014) Transamidation of gluten proteins during the bread-making process of wheat flour to produce breads with less immunoreactive gluten. Food Funct 5: 1813-1818.
13. Matthias T, Jeremias P, Neidhöfer S, et al. (2016) The industrial food additive microbial transglutaminase, mimics the tissue transglutaminase and is immunogenic in celiac disease patients. Autoimmun Rev DOI: 10.1016/j.autrev.2016.09.011.
14. Suwarnalata G, Tan AH, Isa H, et al. (2016) Augmentation of autoantibodies by Helicobacter pylori in Parkinson's disease patients may be linked to greater severity. Plos One 11: e0153725.
15. çamci G, Oguz S (2016) Association between Parkinson's disease and Helicobacter Pylori. J Clin Neurol 12: 147-150.
16. Dow CT (2014) M. paratuberculosis and Parkinson's disease-is this a trigger. Med Hypotheses 83: 709-712.
17. Scheperjans F, Aho V, Pereira PA, et al. (2015) Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 30: 350-358.
18. Loeffler DA, LeWitt PA, Camp DM (2016) Nocardia asteroids-Induced movement abnormalities in mice: Relevance for Parkinson's disease. Mov Disord 31: 1134-1138.
19. Fasano A, Visanji NP, Liu LW, et al. (2015) Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol 14: 625-639.
20. Dobbs SM, Dobbs RJ, Weller C, et al. (2016) Peripheral aetiopathogenic drivers and mediators of Parkinson's disease and co-morbidities: role of gastrointestinal microbiota. J Neurovirol 22: 22-32.
21. Mulak A, Bonaz B (2015) Brain-gut-microbiota axis in Parkinson's disease. World J Gastroenterol 21: 10609-10620.
22. Singhrao SK, Harding A, Poole S, et al. (2015) Porphyromonas gingivalis periodontal infection and its putative links with Alzheimer's disease. Mediators Inflamm 2015: 137357.
23. Bu XL, Yao XQ, Jiao SS, et al. (2015) A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol 22: 1519-1525.
24. Maheshwari P, Eslick GD (2016) Bacterial infection increases the risk of Alzheimer's disease: an evidence-based assessment. J Alzheimers Dis: 1-10.
25. Lerner A, Matthias T (2015) Food industrial microbial transglutaminase in celiac disease: treat or trick. International J Celiac Dis 3: 1-6.
26. Hasegawa S, Goto S, Tsuji H, et al. (2015) Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease. Plos One 10: e0142164.
27. Julio-Pieper M, Bravo JA (2016) Intestinal barrier and behavior. Int Rev Neurobiol 131: 127-141.
28. Snoek SA, Verstege MI, Boeckxstaens GE (2010) The enteric nervous system as a regulator of intestinal epithelial barrier function in health and disease. Expert Rev Gastroenterol Hepatol 4: 637-651.
29. César Machado MC, da Silva FP (2016) Intestinal barrier dysfunction in human pathology and aging. Curr Pharm Des 22: 4645-4650.
30. Buscarinu MC, Cerasoli B, Annibali V, et al. (2016) Altered intestinal permeability in patients with relapsing-remitting multiple sclerosis: a pilot study. Mult Scler Jun: 1352458516652498.
31. Yu YB, Li YQ (2014) Enteric glial cells and their role in the intestinal epithelial barrier. World J Gastroenterol 20: 11273-11280.
32. Yu J, Pian Y, Ge J, et al. (2015) Functional and structural characterization of the antiphagocytic properties of a novel transglutaminase from Streptococcus suis. J Biol Chem 290: 19081-19092.
33. Yang XP, Fu JY, Yang RC, et al. (2016) EGFR transactivation contributes to neuroinflammation in Streptococcus suis meningitis. J Neuroinflammation 13: 274.
34. Sun Y, Li N, Zhang J, et al. (2016) Enolase of Streptococcus suis serotype 2 enhances blood-brain barrier permeability by inducing IL-8 release. Inflammation 39: 718-726.